FULCRUM THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
FULCRUM THERAPEUTICS, INC. (FULC) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$4.81 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$1.05M, a 278.36% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.77M.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $2.29M.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.49M, a 14.30% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$825.00K, a 248.65% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $555.00K, a 71.54% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $1.95M, a 1.32% decline from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $1.98M, a 32.99% decline from fiscal 2019.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.05M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | -$4.81M S-4 · filed 2026-09-02 | -$2.52M derived: sum of 3 quarters · filed 2026-09-02 | -$1.03M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | -$3.77M 10-Q · filed 2026-04-27 | -$1.48M derived: sum of 2 quarters · filed 2026-09-02 | $12.00K derived: sum of 3 quarters · filed 2026-09-02 | $599.00K derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $2.29M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $3.78M derived: sum of 2 quarters · filed 2026-09-02 | $4.37M derived: sum of 3 quarters · filed 2026-09-02 | $1.02M S-4 · filed 2026-09-02 |
| 2025-09-30 | $1.49M derived: 10-Q 9 month − S-4 6 month · filed 2025-10-29 | $2.07M derived: sum of 2 quarters · filed 2026-09-02 | -$1.27M 10-Q · filed 2025-10-29 | -$1.91M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $587.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | -$2.75M S-4 · filed 2026-09-02 | -$3.39M derived: sum of 3 quarters · filed 2026-09-02 | -$2.09M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | -$3.34M 10-Q · filed 2026-04-27 | -$3.98M derived: sum of 2 quarters · filed 2026-09-02 | -$2.68M derived: sum of 3 quarters · filed 2026-09-02 | -$451.00K derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | -$640.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $661.00K derived: sum of 2 quarters · filed 2026-09-02 | $2.89M derived: sum of 3 quarters · filed 2026-09-02 | -$1.03M S-4 · filed 2026-09-02 |
| 2024-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $3.53M derived: sum of 2 quarters · filed 2025-10-29 | -$392.00K 10-Q · filed 2025-10-29 | $517.00K derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$1.69M 10-Q · filed 2025-07-29 | -$784.00K derived: sum of 3 quarters · filed 2025-07-29 | -$1.09M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | -$3.92M 10-Q · filed 2025-05-01 | -$3.01M derived: sum of 2 quarters · filed 2025-05-01 | -$3.32M derived: sum of 3 quarters · filed 2025-05-01 | -$2.55M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $603.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.37M derived: sum of 3 quarters · filed 2025-02-25 | -$825.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $465.00K derived: sum of 2 quarters · filed 2024-11-13 | -$1.73M 10-Q · filed 2024-11-13 | -$172.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $771.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$1.43M 10-Q · filed 2024-07-31 | $134.00K derived: sum of 3 quarters · filed 2024-07-31 | -$4.32M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | -$2.20M 10-Q · filed 2024-05-13 | -$637.00K derived: sum of 2 quarters · filed 2024-05-13 | -$5.09M derived: sum of 3 quarters · filed 2024-05-13 | $753.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$2.89M derived: sum of 2 quarters · filed 2024-02-27 | $2.95M derived: sum of 3 quarters · filed 2024-02-27 | $555.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.39M derived: sum of 2 quarters · filed 2023-11-07 | -$1.01M 10-Q · filed 2023-11-07 | -$1.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $5.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.45M 10-Q · filed 2023-08-03 | $2.65M derived: sum of 3 quarters · filed 2023-08-03 | $5.00M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$2.40M 10-Q · filed 2023-05-15 | -$3.19M derived: sum of 2 quarters · filed 2023-06-26 | -$844.00K derived: sum of 3 quarters · filed 2023-06-26 | $1.57M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | -$795.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $1.55M derived: sum of 2 quarters · filed 2023-06-26 | $3.97M derived: sum of 3 quarters · filed 2023-06-26 | $1.95M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.76M derived: sum of 2 quarters · filed 2022-11-08 | $2.75M 10-Q · filed 2022-11-08 | $1.28M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $397.00K 10-Q · filed 2022-08-11 | -$1.07M derived: sum of 3 quarters · filed 2023-06-26 | $2.36M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | -$2.02M 10-Q · filed 2022-05-09 | -$3.48M derived: sum of 2 quarters · filed 2023-06-26 | -$49.00K derived: sum of 3 quarters · filed 2023-06-26 | $51.00K derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | -$1.47M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $1.97M derived: sum of 2 quarters · filed 2023-06-26 | $2.07M derived: sum of 3 quarters · filed 2023-06-26 | $1.98M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.53M derived: sum of 2 quarters · filed 2021-11-04 | $3.44M 10-Q · filed 2021-11-04 | $5.15M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $9.00K 10-Q · filed 2021-08-10 | $1.72M derived: sum of 3 quarters · filed 2023-06-23 | $2.56M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | -$91.00K 10-Q · filed 2021-05-06 | $1.62M derived: sum of 2 quarters · filed 2023-06-23 | $2.46M derived: sum of 3 quarters · filed 2023-06-23 | $3.67M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | $1.71M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $2.55M derived: sum of 2 quarters · filed 2023-06-23 | $3.76M derived: sum of 3 quarters · filed 2023-06-23 | $2.95M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $838.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.04M derived: sum of 2 quarters · filed 2020-11-10 | $1.24M 10-Q · filed 2020-11-10 | $1.40M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $399.00K 10-Q · filed 2020-08-11 | $560.00K derived: sum of 3 quarters · filed 2020-08-11 | $1.61M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$807.00K 10-Q · filed 2020-05-13 | -$646.00K derived: sum of 2 quarters · filed 2020-05-13 | $400.00K derived: sum of 3 quarters · filed 2020-05-13 | |
| 2018-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $1.21M derived: sum of 2 quarters · filed 2020-03-05 | $1.22M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.06M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $16.00K 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |